TP53 and neoplasm: This is in line with our previous results in gastric cancer, where we showed that CIP2A expression associates with reduced survival in the subgroups of small tumours and p53-immunopositive tumours (Khanna et al, 2009), and in tongue cancer, where we demonstrated that CIP2A serves as an independent marker of reduced survival (Böckelman et al, 2011).